IFNy Dosage Protocol for Sepsis

According to previous publication in human sepsis, a dose of 100mcg of IFNγ (Imukin®, Boehringer, Ingelheim, Germany) was subcutaneously injected for 3 to 5 days (cohort 1) or on days 2–4–7-9-11 (cohort 2) as reported [6 (link), 9 (link), 18 (link), 19 (link)]. The treatment was repeated to reach an increased mHLA-DR expression above 8000 AB/C (cohort 1) or MFI > 20 in cohort 2 (low threshold fixed at MFI 20). Clinical tolerance and systemic or local (injection site) symptoms of inflammation were carefully checked.

Free full text: Click here

Payen D., Faivre V., Miatello J., Leentjens J., Brumpt C., Tissières P., Dupuis C., Pickkers P, & Lukaszewicz A.C. (2019). Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. BMC Infectious Diseases, 19, 931.

Publication 2019

Imukin

Human Ifnγ Inflammation Sepsis Tolerance

Corresponding Organization :

Other organizations : Hôpital Fernand-Widal, Hôpital Saint-Louis, Institut de Biologie Intégrative de la Cellule, Radboud University Nijmegen, Radboud University Medical Center, Hôpital Lariboisière

Top 5 similar protocols

Variable analysis

independent variables

Dose of IFNγ (Imukin®, Boehringer, Ingelheim, Germany): 100mcg
Injection frequency: 3 to 5 days (cohort 1) or on days 2–4–7-9-11 (cohort 2)

dependent variables

MHLA-DR expression above 8000 AB/C (cohort 1) or MFI > 20 (cohort 2)
Clinical tolerance and systemic or local (injection site) symptoms of inflammation

control variables

Not explicitly mentioned

controls

No positive or negative controls were explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!